$DOCS

Sitaram Siddharth sold $50K of DOCS

Sitaram Siddharth (Interim PAO) sold 2,444 shares of Doximity, Inc. (DOCS) at $20.41 on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sitaram Siddharth
Published Jun 10, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DOCS
Neutral
high confidence
Mentioned
$DOCS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DOCSNeutralLow
01

Why it matters

The disclosure confirms an officer’s scheduled open-market sale of DOCS shares; absent additional context, it is usually not a fundamental catalyst.

02

Market read

Confirms modest insider selling in DOCS under a 10b5-1 plan; likely limited trading impact.

03

What to watch

Traders may ignore that the sale date (2026-06-08) precedes the filing; any price reaction would be more likely tied to other contemporaneous news than this Form 4.

Relevance 2/10Novelty 8/10Timing: filed 2026-06-10 (sale dated 2026-06-08)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Doximity, Inc.

Company-level read

Ticker impact

$DOCSNeutralHigh confidence
Context

Insider Form 4 shows Doximity officer Sitaram Siddharth sold 2,444 shares in an open-market transaction on 2026-06-08 under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a disclosed insider sale (not a buy), but it is explicitly under a pre-arranged 10b5-1 plan and the disclosed size is modest versus typical liquidity.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is on a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Doximity, Inc.

    DOCS, the company whose insider transaction is disclosed.

  • Sitaram Siddharth

    Interim PAO who sold 2,444 shares under a 10b5-1 plan.

  • 10b5-1 plan

    Pre-arranged plan that reduces interpretability of insider intent.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance

Doximity's former chief revenue officer, Paul Jorgensen, was ordered to pay $490,000 to the SEC for insider trading. He sold shares based on nonpublic information ahead of negative earnings announcements, avoiding losses and making $2.2 million in profits. Jorgensen was also sentenced to 26 months in prison and ordered to forfeit $2.5 million in a parallel criminal case.

$DOCSMed

Doximity stock falls as Freedom Capital cuts to hold

Doximity Inc (DOCS) shares dropped 5.6% after Freedom Capital downgraded it to Hold, raising its price target to $27. The company beat Q1 estimates, increased full-year revenue guidance, but lowered EBITDA outlook due to AI investment. Freedom Capital noted strong AI search traction but margin concerns and core business softening.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 2027 revenue of $156.6 million, up 7% year over year, and adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million. It said AI workflow and scribe usage grew, repurchased $91.6 million of stock, and ended June 30 with $688 million in cash and marketable securities.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.